Alnylam Pharmaceuticals/$ALNY
1D1W1MYTD1Y5YMAX
Capital at risk
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
- Ticker
- $ALNY
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,500
- Headquarters
- Cambridge, United States
- Website
- www.alnylam.com
ALNY Metrics
BasicAdvanced
$33B
43.69
$5.62
0.27
-
Price and volume
Market cap
$33B
Beta
0.27
52-week high
$495.55
52-week low
$197.81
Average daily volume
1.6M
Financial strength
Current ratio
3.055
Quick ratio
2.791
Long term debt to equity
1.981
Total debt to equity
2.206
Interest coverage (TTM)
3.52%
Profitability
EBITDA (TTM)
1,054.538
Gross margin (TTM)
79.65%
Net profit margin (TTM)
16.13%
Operating margin (TTM)
20.81%
Effective tax rate (TTM)
-1.10%
Revenue per employee (TTM)
$1,920,000
Management effectiveness
Return on assets (TTM)
12.34%
Return on equity (TTM)
96.55%
Valuation
Price to earnings (TTM)
43.69
Price to revenue (TTM)
6.774
Price to book
24.25
Price to tangible book (TTM)
24.25
Price to free cash flow (TTM)
39.692
Free cash flow yield (TTM)
2.52%
Free cash flow per share (TTM)
6.185
Growth
Revenue change (TTM)
95.14%
Earnings per share change (TTM)
-353.96%
3-year revenue growth (CAGR)
57.17%
10-year revenue growth (CAGR)
66.17%
3-year earnings per share growth (CAGR)
-13.27%
10-year earnings per share growth (CAGR)
2.86%
What the Analysts think about ALNY
Analyst ratings (Buy, Hold, Sell) for Alnylam Pharmaceuticals stock.
Analyst projections of the future price of Alnylam Pharmaceuticals stock.
Bulls say / Bears say
Global net product revenues of $1.17 billion in Q2 (up 74% YoY), driven by total TTR revenues of $1.03 billion (89% growth), demonstrate Alnylam’s leadership in RNAi therapies for ATTR amyloidosis (Investing.com).
Alnylam initiated two Phase 2 studies—ALN-6400 in von Willebrand disease and mivelsiran in Down syndrome-associated Alzheimer’s disease—broadening its clinical pipeline beyond the TTR franchise (Investing.com).
The exclusive agreement with BeOne Medicines to commercialize Amvuttra in mainland China and Macau opens a significant growth market, enhancing geographic diversification once local approval is secured (Investing.com).
Q2 revenue of $1.29 billion missed analysts’ $1.32 billion estimate and the company cut full-year TTR guidance to $4.2–$4.5 billion, triggering a 25.7% pre-market share decline as investors reacted to normalization concerns (Investing.com).
GAAP and non-GAAP R&D expenses surged in Q2 driven by costly Phase 3 programs—namely ZENITH, TRITON-CM and TRITON-PN—pressuring operating margins at a time when pipeline readouts are still pending (FT.com).
Total TTR revenues of $1.03 billion accounted for the lion’s share of global net product growth (up 89% YoY), highlighting revenue concentration risk: any setback in the ATTR franchise could materially dent top-line momentum (Investing.com).
Data summarised monthly by Lightyear AI. Last updated on 26 Aug 2026.
ALNY Financial Performance
Revenues and expenses
ALNY Earnings Performance
Company profitability
Upcoming events
No upcoming events
ALNY News
AllArticlesVideos
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
Business Wire2 weeks ago
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
Business Wire3 weeks ago
Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026
Business Wire4 weeks ago
Funds containing ALNY
AllUSDGBPEUR
Fund name | Fund size | $ALNY weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 2.16% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 2.16% |
Amundi S&P 500£500G | £6.6B | 0.63% |
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 0.54% |
iShares MSCI USA SRI$SUAS | $3.4B | 0.23% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.